MedPath

A feasibility study of dose-dense epirubicin and cyclophosphamide for primary breast cancer in neoadjuvant and adjuvant setting

Not Applicable
Conditions
Primary breast cancer
Registration Number
JPRN-UMIN000016213
Lead Sponsor
agoya University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with active infection need to treat systemic therapy, nursing, mental disorder, or other uncontrolled medical conditions are excluded.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath